Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-1 MP safety and tolerability study in adults with alpha-1 antitrypsin deficiency
2005-002402-36Phase 3Completed
- Sponsor
- Talecris Biotherapeutics
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of alpha-1-proteinase inhibitor in alpha-1 antitrypsin deficiency (AATD), sponsored by Talecris Biotherapeutics. Primary endpoint: Treatment-emergent adverse events. Started Feb 2006; status: completed.
02
Drugs
alpha-1-proteinase inhibitor
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on 2005-002402-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002402-36.